CLINICAL_TRIALS
trial_result
· 2019-07-29
Clinical Trial Update: Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years [Phase 2]
Summary
Phase 2 trial update for the ChimeriVax tetravalent dengue vaccine in healthy children aged 2-11 years; study completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Dengue Virus, Dengue Fever | Phase 2 | Status: COMPLETED | Results posted: 2019-07-29